KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizationAmortizationCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in CashChange in IntangiblesChange in IntangiblesDivestmentsDividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShares IssuedShares RepurchasedShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gsk (GSK) Cash from Investing Activities (2016 - 2026)

Gsk has reported Cash from Investing Activities over the past 18 years, most recently at -$2.0 billion for Q1 2026.

  • For Q1 2026, Cash from Investing Activities fell 37.17% year-over-year to -$2.0 billion; the TTM value through Mar 2026 reached -$3.9 billion, down 52.28%, while the annual FY2025 figure was -$5.6 billion, 256.95% down from the prior year.
  • Cash from Investing Activities for Q1 2026 was -$2.0 billion at Gsk, down from -$1.2 billion in the prior quarter.
  • Over five years, Cash from Investing Activities peaked at $797.1 million in Q4 2024 and troughed at -$4.9 billion in Q4 2022.
  • A 5-year average of -$1.8 billion and a median of -$1.4 billion in 2025 define the central range for Cash from Investing Activities.
  • Biggest five-year swings in Cash from Investing Activities: crashed 7184.1% in 2022 and later soared 146.81% in 2024.
  • Year by year, Cash from Investing Activities stood at -$4.9 billion in 2022, then skyrocketed by 64.92% to -$1.7 billion in 2023, then soared by 146.81% to $797.1 million in 2024, then tumbled by 255.7% to -$1.2 billion in 2025, then crashed by 59.26% to -$2.0 billion in 2026.
  • Business Quant data shows Cash from Investing Activities for GSK at -$2.0 billion in Q1 2026, -$1.2 billion in Q4 2025, and -$1.4 billion in Q1 2025.